Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Author: Pleyer Lisa   Döhner Hartmut   Dombret Hervé   Seymour John F.   Schuh Andre C.   Beach CL   Swern Arlene S.   Burgstaller Sonja   Stauder Reinhard   Girschikofsky Michael   Sill Heinz   Schlick Konstantin   Thaler Josef   Halter Britta   Machherndl Spandl Sigrid   Zebisch Armin   Pichler Angelika   Pfeilstöcker Michael   Autzinger Eva M.   Lang Alois   Geissler Klaus   Voskova Daniela   Sperr Wolfgang R.   Hojas Sabine   Rogulj Inga M.   Andel Johannes   Greil Richard  

Publisher: MDPI

E-ISSN: 1422-0067|18|2|415-415

ISSN: 1422-0067

Source: International Journal of Molecular Sciences, Vol.18, Iss.2, 2017-02, pp. : 415-415

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content